Vadel

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vadel

Vadel is a prescription-only medication primarily classified as a hypolipidemic agent used to help manage high cholesterol levels. It is defined pharmacologically as a selective cholesterol absorption inhibitor, a distinct classification that sets it apart from traditional therapies.

Property Description
Active Ingredient Ezetimibe
Form Oral Tablet
Pharmacological Class Cholesterol absorption inhibitor
Common Purpose Lowering elevated cholesterol (LDL)
Origin Synthetic 2-azetidinone agent

What Type of Medicine is Vadel? (Definition and Classification)

Vadel is a non-statin medicine belonging to the cholesterol absorption inhibitor class, designed to specifically reduce elevated lipids in the bloodstream. Its classification falls under the group of hypolipidemians used in the management of dyslipidemia. Vadel’s composition, featuring the active agent Ezetimibe, is used for its lipid-lowering capabilities. It functions as a selective inhibitor of intestinal cholesterol absorption and serves as a key agent in the treatment of hyperlipidemia.


Ezetimibe: Vadel's Composition, Form, and Origin

The active ingredient in Vadel is Ezetimibe, a synthetic small molecule originating from the 2-azetidinone class of agents. Vadel is supplied as a tablet for oral administration and is classified as a single-ingredient product (monotherapy). The medication works by inhibiting the NPC1L1 protein, which is essential for cholesterol absorption. As a monotherapy product, Vadel provides therapeutic flexibility, allowing for customized combination therapy when necessary.


What is Vadel's General Purpose? (High-Level Mechanism and Benefit)

Vadel's general purpose is to effectively contribute to lowering elevated cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. The drug achieves this by selectively blocking the absorption of cholesterol in the small intestine, targeting a specific transport protein known as Niemann-Pick C1-Like 1 (NPC1L1). By limiting the amount of cholesterol delivered from the gut to the liver, Vadel reduces the overall cholesterol burden, serving as a strategy in long-term lipid management for individuals diagnosed with hypercholesterolemia.

What side effects are possible with Vadel?

Possible side effects and safety information

The official safety documentation for Vadel (Ezetimibe) classifies possible side effects according to standard regulatory frequency categories, structuring the medicine’s risk profile based on clinical trial and post-marketing data.


Adverse Reaction Categories

Adverse reactions are documented across various physiological systems, including Gastrointestinal disorders, Musculoskeletal and connective tissue disorders, and Infections and infestations. The frequency is categorized as follows:

  • Common effects, reported frequently in clinical trials, include upper respiratory tract infection, diarrhea, arthralgia (joint pain), fatigue, and headache.
  • Uncommon effects include conditions such as nausea, hypertension, rash, muscle spasms, and elevations in certain laboratory parameters like Blood CPK or Liver function tests.
  • Reactions reported in Post-Marketing Surveillance (frequency Not Known) include severe events such as Hepatitis, Pancreatitis, Thrombocytopaenia, and serious Hypersensitivity reactions (e.g., angio-oedema).

Serious Safety Considerations

The regulatory labeling specifically highlights the potential for Myopathy and Rhabdomyolysis, which are recognized as serious skeletal muscle-related events. Severe Hypersensitivity Reactions and significant, persistent elevations in hepatic transaminases are also categorized as clinically important adverse reactions.

Safety Restrictions and Limitations:

Use of Vadel is not recommended in individuals with moderate or severe hepatic impairment (Child-Pugh B or C). The medication is contraindicated in patients with a known hypersensitivity to Ezetimibe or any component of the formulation. Furthermore, specific constraints apply during co-administration: for example, the label mandates monitoring of Cyclosporine concentrations if used concomitantly.


The comprehensive classification of adverse reactions by frequency and physiological system provides the necessary regulatory framework to understand the known safety profile of Vadel.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding Vadel (Ezetimibe) overdose is based on findings documented in authoritative government regulatory sources.


Documented Overdose Profile

The official prescribing information indicates a high degree of tolerability for the active ingredient, Ezetimibe. Documented studies of single exposures up to 50 mg and chronic daily exposures up to 120 mg show that no significant clinical or laboratory adverse events were observed. Consequently, regulatory documents do not list a specific set of symptoms or a formal severity classification for acute overdose of Vadel monotherapy. The official labeling explicitly states that no specific antidote is known to counteract the effects of Vadel overdose.


Emergency Actions Mandated by Regulators

The primary requirement established by regulatory guidance is the need for immediate medical attention upon the suspicion of overdose, regardless of the absence of immediate symptoms. Patients or caregivers must contact a Poison Control Center or seek emergency room services immediately.

Overdose management is directed to providing symptomatic and supportive care. This standardized approach addresses any potential clinical changes in the patient. Furthermore, official guidance may require monitoring, such as obtaining Liver Function Tests (LFTs), if hepatotoxicity is suspected during the post-exposure observation period.

Therapeutic Uses of Vadel

Vadel (Ezetimibe) is commonly used to help manage dyslipidemia, a systemic imbalance characterized by abnormally elevated lipids in the bloodstream. Vadel may assist with addressing this condition by primarily targeting LDL-C and Total Cholesterol. This therapeutic domain is relevant in situations where patients require supportive management beyond dietary changes. The medication is used for managing conditions such as primary hypercholesterolemia, mixed dyslipidemia, Homozygous Familial Hypercholesterolemia (HoFH), and Sitosterolemia.

Core Therapeutic Benefits

The medicine supports the long-term goal of may assist with addressing the systemic threat posed by high cholesterol, which contributes to supporting cardiovascular stability. It is commonly used to help with conditions that require additional symptomatic support, often in combination with statins to support enhanced lowering of LDL-C or as a monotherapy for statin intolerance. The medicine is considered relevant for managing the overall symptom load and supporting patients during difficult episodes.


Quick Fact: Supportive Management of Elevated Lipid Profile Vadel supports the reduction of LDL-C and Total Cholesterol found in the blood, contributing to supports general well-being during periods of chronic systemic imbalance.

Regulatory References

  1. DailyMed database hosted by the NIH

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vadel? — Official Regulatory Information


Eligibility Scope

This medicine is authorized only for adult patients (18 years of age and older). Eligibility is strictly defined by the specific form and stage of the underlying disease, transthyretin-mediated amyloidosis (ATTR).

Population Eligibility Classification Condition / Restriction
Adults with ATTR-CM Eligible Must have cardiomyopathy of wild-type or hereditary ATTR.
Adults with ATTR-PN Eligible Must have Stage 1 symptomatic polyneuropathy.
Pediatric Patients Not Established Safety and effectiveness have not been established.
NYHA Class IV Heart Failure Not Recommended Benefit was not demonstrated in this advanced disease stage.
Post-Transplant Patients Not Recommended Use is not recommended following liver or heart transplant.
Known Hypersensitivity Contraindicated Use is prohibited if there is a known hypersensitivity to the active substance or any excipients.

Use in Specific Populations

Use during pregnancy is not recommended as the medicine may cause fetal harm based on animal study findings. Women of childbearing potential should use effective contraception during treatment and for one month after stopping. Breastfeeding is not recommended due to the potential for serious adverse reactions in the infant. While no dosage adjustment is required for the elderly, use is limited in patients with severe hepatic or renal impairment due to a lack of complete study data.

What should I know about interactions with other medicines?

Vadel Interactions with other medicines and products

Regulatory documents define Vadel’s (Ezetimibe) interaction profile based primarily on pharmacokinetic and pharmacodynamic mechanisms, not major metabolic pathways. Vadel is officially stated to have no clinically significant effect on the major Cytochrome P450 isozymes (CYP1A2, 2D6, 2C8/9, 3A4), indicating a low risk of metabolic drug-drug interaction.

Pharmacokinetic Exposure Changes

Interaction with certain medicines alters Vadel’s systemic exposure, which is governed by transport mechanisms and enterohepatic circulation:

Interacting Substance Official Exposure Outcome
Cyclosporine Substantial increase (AUC uparrow approximately mathbf240%)
Bile Acid Sequestrants (e.g., Cholestyramine) Significant reduction (AUC downarrow approximately mathbf55%)

Administration Rules and Restrictions

Co-administration with Bile Acid Sequestrants requires a specific separation of doses to maintain Vadel’s intended exposure. Vadel must be administered at least 2 hours before or 4 hours after the sequestrant.

Co-administration with Fibrates is classified as high-risk. This restriction is based on a documented pharmacodynamic risk of cholelithiasis and severe muscle-related effects. Consequently, Vadel (Ezetimibe) is not recommended with fibrates other than fenofibrate, and is officially contraindicated with Gemfibrozil when used in combination with a statin. Additionally, Vadel may potentiate the effect of Coumarin Anticoagulants, requiring monitoring of the International Normalized Ratio (INR).

Mechanism of Action

Vadel's mechanism begins in the small intestine, where its active component, Ezetimibe, functions as a selective inhibitor of the NPC1L1 protein. This critical membrane transporter is responsible for the uptake of cholesterol from the gut lumen. By binding to NPC1L1, Vadel directly blocks the absorption of cholesterol, reducing the amount delivered to the liver and initiating the systemic cascade.

The reduced supply of cholesterol to the liver triggers a physiological compensation mechanism known as hepatic cholesterol homeostasis. The liver responds to its depleted internal stores by increasing the expression and surface density of Low-Density Lipoprotein (LDL) Receptors. This enhanced receptor activity functions to accelerate the clearance of LDL cholesterol particles from the circulating bloodstream, resulting in the net physiological effect.

The mechanism is subject to a natural feedback limitation: the drop in liver cholesterol can simultaneously stimulate the production of cholesterol within the liver itself via the HMG-CoA reductase pathway. This inherent compensatory increase in internal synthesis can partially attenuate the change in LDL receptor expression resulting from the initial NPC1L1 blockade.

Dosage and Administration Information

How to Use Vadel

Vadel (Ezetimibe) is an oral medication with a standardized dosing regimen, administered as part of a long-term plan for managing lipid levels. The official guidelines establish a simple, fixed-dose pattern that is consistent across major indications, minimizing the complexity of administration for most patients.


Official Administration Guidelines

Vadel is supplied as a tablet for oral administration.

Instruction Detail
Standard Dose & Frequency A fixed dose of 10 mg is taken once daily (QD). This is the starting dose and the maximum recommended dose.
Timing & Food The tablet may be taken with or without food at any time of the day.
Missed Dose If a dose is missed, it should be taken as soon as it is remembered, but the next dose should not be doubled to compensate.

Usage Constraints and Specific Populations

Special Procedural Conditions: When Vadel is administered concurrently with a bile acid sequestrant (such as cholestyramine), a separation period is required. Vadel must be taken at least 2 hours before or at least 4 hours after the administration of the sequestrant.

Population Guidelines: The labeled dose of 10 mg once daily requires no initial adjustment for older adults or for patients with renal impairment. Similarly, no dosage change is required for individuals with mild hepatic impairment. For pediatric patients aged 10 years and older, the official dose is 10 mg once daily.

Recent Clinical Evidence

Research evidence / Overview of studies for Vadel

Vadel (Ezetimibe) was evaluated in research exploring several clinical conditions primarily characterized by elevated lipid levels. The research base is built upon multiple types of studies, ranging from large, long-term Randomized Controlled Trials (RCTs) to smaller studies focused on rare genetic disorders. The evidence highlights what is known—and what is still uncertain—about its evaluation, according to official and peer-reviewed scientific sources.


Evidence for Use in Primary Hypercholesterolemia and Mixed Dyslipidemia

Research has primarily examined Vadel in the context of Primary Hypercholesterolemia (high LDL cholesterol) and Mixed Dyslipidemia (high LDL cholesterol and triglycerides). Large-scale clinical trials, known as Randomized Controlled Trials (RCTs), was studied for use both as a stand-alone therapy (monotherapy) and as an add-on to statin treatments. These studies monitored Lipid Biomarkers (measurements of cholesterol like LDL-C and Total Cholesterol) and Major Adverse Cardiovascular Events (MACE) over many years.

Research highlights changes measured during the study period where Vadel was administered. These findings describe patterns related to the measured levels of LDL-C and Total Cholesterol in the blood. When studied for use as an add-on to statin therapy, the research describes data showing patterns related to the occurrence of MACE compared to statin therapy alone. The evidence primarily focused on populations with existing cardiovascular disease or severe lipid elevation.

Evidence for Use in Rare Genetic Lipid Disorders

The research for Vadel also extends to two very rare, severe genetic conditions: Homozygous Familial Hypercholesterolemia (HoFH) and Homozygous Sitosterolemia (HomS). These small studies primarily examined the measured outcomes related to Lipid Biomarkers for HoFH and Plasma Plant Sterols for HomS. Because these are extremely rare conditions, the sample sizes were modest. The evidence largely relies on measurements of biomarkers (surrogate endpoints); research describing long-term cardiovascular event patterns is limited.

What is Still Uncertain About Vadel's Research Base

Vadel was evaluated in a number of studies; however, some areas of the research base may still be considered limited by scientific standards. Comparative evidence is lacking for some combinations, and there is limited information for long-term outcomes when Vadel was studied for use strictly as monotherapy (alone). Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Vadel (FAQ)


Q: What is Vadel used for besides its main purpose?

The official product information states that Vadel is used to reduce high LDL cholesterol in patients with Primary Hyperlipidemia. It is also indicated for patients diagnosed with Homozygous Sitosterolemia, which is a very rare inherited condition that causes high levels of plant sterols in the blood. These are the approved uses described in regulatory documents.


Q: Is Vadel a type of antidepressant?

No, Vadel is a medication specifically classified as a selective cholesterol absorption inhibitor. This non-statin drug is part of a therapeutic class used to lower lipid (fat) levels in the blood. Regulatory documents describe its function as related only to cholesterol management.


Q: How quickly does Vadel start to work?

Studies indicate that the active form of Vadel reaches its highest concentration in the bloodstream very quickly, often within 1 to 2 hours after the medication is administered. However, the full measurable effect on cholesterol reduction typically takes longer.


Q: How long do the effects of Vadel typically last?

Official pharmacokinetic information states that the half-life of the active ingredient is approximately 22 hours. This duration supports the general dosing frequency of once daily.


Q: Does Vadel cause weight gain?

Based on the official safety reports, weight gain is not listed as a common or uncommon adverse reaction associated with Vadel. Known side effects are categorized based on frequency from clinical trial data.


Q: Is Vadel a long-term treatment or is it usually temporary?

According to the official product information, Vadel is intended to be administered as part of a long-term plan for managing elevated lipid levels. Lipid management is typically a chronic, ongoing treatment strategy.


Q: Where can I find official information about Vadel's safety profile?

The most complete official information regarding the drug’s safety profile, side effects, and prescribing details can be found in the regulatory documents. Specifically, the full drug label files provided by the FDA and DailyMed contain this comprehensive information.


Q: Can Vadel interact with herbal supplements?

While the regulatory label lists specific drug-to-drug interactions, it does not specifically test or list every possible interaction with herbal remedies or supplements. Official guidance often recommends disclosing all supplements to a healthcare provider, as they are not tested in the same manner as prescription medicines.


Q: Does Vadel affect sleep?

Regulatory-sourced clinical data notes that trouble sleeping (insomnia) is a reported adverse reaction. This is not classified as a common side effect, but it has been observed in some patient reports.


Q: Is Vadel available in generic form?

Yes, the active ingredient in Vadel, ezetimibe, has been approved by the FDA as a generic drug. This means that approved generic equivalents are available on the market.


Q: Can I take Vadel if I am already taking vitamins?

The official drug label does not list any specific interactions with standard vitamins. However, the regulatory label indicates that patients should disclose all medications, supplements, herbs, and vitamins to their healthcare provider to screen for potential interactions.


Q: What should I avoid drinking while taking Vadel?

Official documents do not list any specific beverages that are strictly prohibited while taking Vadel. However, official documentation suggests caution regarding alcohol consumption, as both alcohol and Vadel may potentially affect the liver, especially if Vadel is combined with a statin.


Q: Does Vadel interact with birth control pills?

Official regulatory information indicates that Vadel does not affect the efficacy of hormonal contraception. This includes birth control pills, patches, or rings.


Q: Is Vadel a controlled substance?

No, the active ingredient in Vadel, ezetimibe, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).


Q: What is the typical timeframe for Vadel to show its full effect?

The official dosage guidelines advise that the reduction in LDL cholesterol should be clinically assessed as early as 4 weeks after the start of therapy. This four-week period is typically when the change in lipid levels becomes measurable.


Q: Do I need to change my diet while taking Vadel?

Yes. The official indications state that Vadel is to be used as an adjunct to diet. This means the medication is intended to be used along with a physician-recommended cholesterol-lowering diet.


Q: Can Vadel cause changes in mood?

The official safety profile notes that changes in mood, such as depression or related feelings like loss of interest, have been reported in post-marketing surveillance. These are events where the frequency is not known.


Q: Is Vadel safe to use if I have high blood pressure?

High blood pressure (hypertension) is listed in the clinical trial data as an uncommon adverse reaction, meaning it occurred infrequently in studies. However, pre-existing high blood pressure is not listed as a specific contraindication or a restriction for using Vadel alone.


Q: Is it normal to feel [vague side effect, e.g., mild dizziness] after starting Vadel?

Official product information lists common side effects such as diarrhea, joint pain, and fatigue. Dizziness is also noted as an adverse reaction that has been reported in certain patient groups.


Q: Does Vadel require regular blood tests?

Official label information advises healthcare providers to assess LDL cholesterol and to perform liver enzyme testing as clinically indicated while the patient is undergoing treatment with Vadel. This monitoring is to ensure the treatment is having its intended effect and to check for potential side effects.


Q: What kind of patient is generally eligible to use Vadel?

Official indications state that Vadel is primarily for adults and pediatric patients 10 years of age and older who have elevated LDL cholesterol due to Primary Hyperlipidemia. It is also indicated for patients with the rare condition Homozygous Sitosterolemia.


Q: How long did the clinical trials for Vadel last?

Research and clinical trials for Vadel have varied in duration. Studies have included short-term efficacy trials as well as long-term observational post-marketing studies that monitored patients for safety and efficacy for 52 weeks or more.


Q: How is Vadel different from a supplement?

Vadel is classified as a prescription-only medication that has undergone rigorous review and FDA approval as a selective cholesterol absorption inhibitor. This distinguishes it from over-the-counter health supplements.


Q: What does the patient leaflet for Vadel say about long-term use?

Since Vadel is part of a long-term treatment plan, official patient information confirms its continued use over time. Long-term post-marketing studies have specifically monitored the safety and efficacy of the drug for durations of 52 weeks or more.


Q: Is Vadel meant to cure or manage the condition?

According to the official indications, Vadel is prescribed as an adjunct to diet to reduce elevated LDL-C. The drug’s purpose is therefore to manage cholesterol levels as part of a chronic care strategy, not to provide a cure.

How should Vadel be stored and disposed of?

How to Store and Dispose of Vadel?

Vadel (Ezetimibe oral tablets) must be handled and stored in accordance with official regulatory requirements to ensure product quality and safety.

Required Storage Conditions

Vadel must be kept at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The tablets must be protected from moisture and stored in their original container or package. For safety, the medicine must be kept out of the sight and reach of children.


Official Disposal Rules

Unused or expired Vadel must not be disposed of in household waste or flushed down the toilet (wastewater). Disposal must follow local regulatory requirements. Consult a pharmacist for instructions on proper discarding to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vadel found in:

A-Z Index: